In last trading session, Journey Medical Corp (NASDAQ:DERM) saw 0.35 million shares changing hands with its beta currently measuring 0.84. Company’s recent per share price level of $7.19 trading at $0.6 or 9.10% at ring of the bell on the day assigns it a market valuation of $166.12M. That closing price of DERM’s stock is at a premium of 4.17% from its 52-week high price of $6.89 and is indicating a premium of 55.49% from its 52-week low price of $3.20. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.11 million shares which gives us an average trading volume of 59.00K if we extend that period to 3-months.
For Journey Medical Corp (DERM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Journey Medical Corp (NASDAQ:DERM) trade information
Upright in the green during last session for gaining 9.10%, in the last five days DERM remained trading in the green while hitting it’s week-highest on Friday, 04/04/25 when the stock touched $7.19 price level, adding 1.37% to its value on the day. Journey Medical Corp’s shares saw a change of 83.89% in year-to-date performance and have moved 17.68% in past 5-day. Journey Medical Corp (NASDAQ:DERM) showed a performance of 42.09% in past 30-days. Number of shares sold short was 0.12 million shares which calculate 2.3 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 10.5 to the stock, which implies a rise of 31.52% to its current value. Analysts have been projecting 10.5 as a low price target for the stock while placing it at a high target of 10.5. It follows that stock’s current price would drop -46.04% in reaching the projected high whereas dropping to the targeted low would mean a loss of -46.04% for stock’s current value.
Journey Medical Corp (DERM) estimates and forecasts
This year revenue growth is estimated to rise 27.28% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 12.05M for the same. And 4 analysts are in estimates of company making revenue of 15.65M in the next quarter. Company posted 13.03M and 14.86M of sales in current and next quarters respectively a year earlier.
Journey Medical Corp (NASDAQ:DERM)’s Major holders
Insiders are in possession of 26.12% of company’s total shares while institution are holding 22.18 percent of that, with stock having share float percentage of 30.02%. Investors also watch the number of corporate investors in a company very closely, which is 22.18% institutions for Journey Medical Corp that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at DERM for having 0.31 million shares of worth $1.75 million. And as of 2024-06-30, it was holding 1.5703 of the company’s outstanding shares.
The second largest institutional holder is CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC., which was holding about 0.29 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.4752 of outstanding shares, having a total worth of $1.66 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 211.45 shares of worth $1.52 million or 1.24% of the total outstanding shares. The later fund manager was in possession of 109.08 shares on Dec 31, 2024 , making its stake of worth around $0.78 million in the company or a holder of 0.64% of company’s stock.
